Literature DB >> 24316826

Structure of the β-form of human MK2 in complex with the non-selective kinase inhibitor TEI-L03090.

Aiko Fujino1, Kei Fukushima, Takaharu Kubota, Yoshiyuki Matsumoto, Midori Takimoto-Kamimura.   

Abstract

Mitogen-activated protein kinase-activated protein kinase 2 (MK2 or MAPKAP-K2), a serine/threonine kinase from the p38 mitogen-activated protein kinase signalling pathway, plays an important role in the production of TNF-α and other cytokines. In a previous report, it was shown that MK2 in complex with the selective inhibitor TEI-I01800 adopts an α-helical glycine-rich loop that is induced by the stable nonplanar conformer of TEI-I01800. To understand the mechanism of the structural change, the structure of MK2 bound to TEI-L03090, which lacks the key substituent found in TEI-I01800, was determined. MK2-TEI-L03090 has a β-sheet glycine-rich loop in common with other kinases, as predicted. This result suggests that a small compound can induce a drastic conformational change in the target protein structure and can be used to design potent and selective inhibitors.

Entities:  

Keywords:  MAPKAP-K2; MK2; conformational change; glycine-rich loop; inhibitors

Mesh:

Substances:

Year:  2013        PMID: 24316826      PMCID: PMC3855716          DOI: 10.1107/S1744309113030534

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  24 in total

1.  Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.

Authors:  Arthur Oubrie; Allard Kaptein; Edwin de Zwart; Niels Hoogenboom; Rianne Goorden; Bas van de Kar; Maaike van Hoek; Vera de Kimpe; Ruud van der Heijden; Judith Borsboom; Bert Kazemier; Jeroen de Roos; Michiel Scheffers; Jos Lommerse; Carsten Schultz-Fademrecht; Tjeerd Barf
Journal:  Bioorg Med Chem Lett       Date:  2011-11-03       Impact factor: 2.823

2.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

3.  Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme.

Authors:  Kathryn W Underwood; Kevin D Parris; Elizabeth Federico; Lidia Mosyak; Robert M Czerwinski; Tania Shane; Meggin Taylor; Kristine Svenson; Yan Liu; Chu-Lai Hsiao; Scott Wolfrom; Michelle Maguire; Karl Malakian; Jean-Baptiste Telliez; Lih-Ling Lin; Ronald W Kriz; Jasbir Seehra; William S Somers; Mark L Stahl
Journal:  Structure       Date:  2003-06       Impact factor: 5.006

4.  Molecular replacement with MOLREP.

Authors:  Alexei Vagin; Alexei Teplyakov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

5.  Structure-based lead identification of ATP-competitive MK2 inhibitors.

Authors:  Tjeerd Barf; Allard Kaptein; Sander de Wilde; Ruud van der Heijden; Richard van Someren; Dennis Demont; Carsten Schultz-Fademrecht; Judith Versteegh; Mario van Zeeland; Nicole Seegers; Bert Kazemier; Bas van de Kar; Maaike van Hoek; Jeroen de Roos; Henri Klop; Ruben Smeets; Claudia Hofstra; Jorrit Hornberg; Arthur Oubrie
Journal:  Bioorg Med Chem Lett       Date:  2011-04-16       Impact factor: 2.823

6.  Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.

Authors:  Tomomi Kosugi; Dale R Mitchell; Aiko Fujino; Minoru Imai; Mika Kambe; Shinji Kobayashi; Hiroaki Makino; Yohei Matsueda; Yasuhiro Oue; Kanji Komatsu; Keiichiro Imaizumi; Yuri Sakai; Satoshi Sugiura; Osami Takenouchi; Gen Unoki; Yuko Yamakoshi; Vicky Cunliffe; Julie Frearson; Richard Gordon; C John Harris; Heidi Kalloo-Hosein; Joelle Le; Gita Patel; Donald J Simpson; Brad Sherborne; Peter S Thomas; Naotaka Suzuki; Midori Takimoto-Kamimura; Ken-ichiro Kataoka
Journal:  J Med Chem       Date:  2012-07-31       Impact factor: 7.446

7.  Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

Authors:  David R Anderson; Marvin J Meyers; William F Vernier; Matthew W Mahoney; Ravi G Kurumbail; Nicole Caspers; Gennadiy I Poda; John F Schindler; David B Reitz; Robert J Mourey
Journal:  J Med Chem       Date:  2007-05-05       Impact factor: 7.446

8.  Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase.

Authors:  L H Tsai; E Harlow; M Meyerson
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

9.  The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor.

Authors:  R Beyaert; A Cuenda; W Vanden Berghe; S Plaisance; J C Lee; G Haegeman; P Cohen; W Fiers
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

10.  Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity.

Authors:  Aiko Fujino; Kei Fukushima; Takaharu Kubota; Tomomi Kosugi; Midori Takimoto-Kamimura
Journal:  J Synchrotron Radiat       Date:  2013-09-26       Impact factor: 2.616

View more
  1 in total

Review 1.  Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.

Authors:  Mario Fiore; Stefano Forli; Fabrizio Manetti
Journal:  J Med Chem       Date:  2015-11-09       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.